Do analysts rate RDHL or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, RDHL or ALVR?

Redhill Biopharma has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Redhill Biopharma $290K 14.14 -$430K $1.05 thousand 0.00 AlloVir N/A N/A -$190.42M -$20.23 N/A

Is RDHL or ALVR more profitable?

Redhill Biopharma's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A AlloVir N/A -71.03% -61.27%

Do analysts prefer CLRB or RDHL?

Cellectar Biosciences currently has a consensus price target of $11.00, indicating a potential upside of 362.38%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Cellectar Biosciences is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CLRB or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% Redhill Biopharma N/A N/A N/A

Do analysts prefer MYNZ or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, MYNZ or RDHL?

Redhill Biopharma has lower revenue, but higher earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $659.94K 23.75 -$21.65M -$65.60 N/A Redhill Biopharma $290K 14.14 -$430K $1.05 thousand 0.00

Is MYNZ or RDHL more profitable?

Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Redhill Biopharma N/A N/A N/A

Do analysts recommend XCUR or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, XCUR or RDHL?

Redhill Biopharma has lower revenue, but higher earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure $500K 35.42 -$4.95M -$1.55 N/A Redhill Biopharma $290K 14.14 -$430K $1.05 thousand 0.00

Is XCUR or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Redhill Biopharma N/A N/A N/A

Does the media favor XCUR or RDHL?

In the previous week, Exicure had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 5 mentions for Exicure and 4 mentions for Redhill Biopharma. Exicure's average media sentiment score of 0.57 beat Redhill Biopharma's score of 0.37 indicating that Exicure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RDHL or MDCX?

Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 2,619.03%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is RDHL or MDCX more profitable?

Redhill Biopharma's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Medicus Pharma N/A -3,137.84% -311.33%

Does the media prefer RDHL or MDCX?

In the previous week, Medicus Pharma had 4 more articles in the media than Redhill Biopharma. MarketBeat recorded 8 mentions for Medicus Pharma and 4 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.37 beat Medicus Pharma's score of 0.30 indicating that Redhill Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medicus Pharma 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Redhill Biopharma (RDHL) Competitors

$0.79 -0.02 (-2.47%)

As of 01:37 PM Eastern

Compare

RDHL vs. ALVR, CLRB, MYNZ, XCUR, and MDCX

Should you buy Redhill Biopharma stock or one of its competitors? MarketBeat compares Redhill Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Redhill Biopharma include AlloVir (ALVR), Cellectar Biosciences (CLRB), Mainz Biomed (MYNZ), Exicure (XCUR), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry.

How does Redhill Biopharma compare to AlloVir?

Redhill Biopharma (NASDAQ:RDHL) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Redhill Biopharma has a beta of 4.98, indicating that its stock price is 398% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

In the previous week, Redhill Biopharma had 4 more articles in the media than AlloVir. MarketBeat recorded 4 mentions for Redhill Biopharma and 0 mentions for AlloVir. Redhill Biopharma's average media sentiment score of 0.37 beat AlloVir's score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Redhill Biopharma	Neutral
AlloVir	Neutral

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Redhill Biopharma's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
AlloVir	N/A	-71.03%	-61.27%

Redhill Biopharma has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.14	-$430K	$1.05 thousand	0.00
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Summary

Redhill Biopharma beats AlloVir on 10 of the 12 factors compared between the two stocks.

How does Redhill Biopharma compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Cellectar Biosciences currently has a consensus price target of $11.00, indicating a potential upside of 362.38%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Cellectar Biosciences is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Redhill Biopharma	$290K	14.14	-$430K	$1.05 thousand	0.00

Redhill Biopharma's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Redhill Biopharma	N/A	N/A	N/A

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Redhill Biopharma had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 4 mentions for Redhill Biopharma and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.43 beat Redhill Biopharma's score of 0.37 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectar Biosciences	Positive
Redhill Biopharma	Neutral

Cellectar Biosciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, indicating that its stock price is 398% more volatile than the broader market.

Summary

Redhill Biopharma beats Cellectar Biosciences on 9 of the 14 factors compared between the two stocks.

How does Redhill Biopharma compare to Mainz Biomed?

Mainz Biomed (NASDAQ:MYNZ) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

7.2% of Redhill Biopharma shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Redhill Biopharma	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, meaning that its stock price is 398% more volatile than the broader market.

Redhill Biopharma has lower revenue, but higher earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	23.75	-$21.65M	-$65.60	N/A
Redhill Biopharma	$290K	14.14	-$430K	$1.05 thousand	0.00

In the previous week, Redhill Biopharma had 4 more articles in the media than Mainz Biomed. MarketBeat recorded 4 mentions for Redhill Biopharma and 0 mentions for Mainz Biomed. Redhill Biopharma's average media sentiment score of 0.37 beat Mainz Biomed's score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Neutral
Redhill Biopharma	Neutral

Summary

Redhill Biopharma beats Mainz Biomed on 7 of the 11 factors compared between the two stocks.

How does Redhill Biopharma compare to Exicure?

Exicure (NASDAQ:XCUR) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Exicure has a beta of 3.53, indicating that its stock price is 253% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, indicating that its stock price is 398% more volatile than the broader market.

Redhill Biopharma's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Redhill Biopharma	N/A	N/A	N/A

In the previous week, Exicure had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 5 mentions for Exicure and 4 mentions for Redhill Biopharma. Exicure's average media sentiment score of 0.57 beat Redhill Biopharma's score of 0.37 indicating that Exicure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.8% of Exicure shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Redhill Biopharma has lower revenue, but higher earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	35.42	-$4.95M	-$1.55	N/A
Redhill Biopharma	$290K	14.14	-$430K	$1.05 thousand	0.00

Summary

Exicure and Redhill Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Redhill Biopharma compare to Medicus Pharma?

Redhill Biopharma (NASDAQ:RDHL) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 2,619.03%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

7.2% of Redhill Biopharma shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by company insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Redhill Biopharma has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.14	-$430K	$1.05 thousand	0.00
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Redhill Biopharma's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Medicus Pharma	N/A	-3,137.84%	-311.33%

In the previous week, Medicus Pharma had 4 more articles in the media than Redhill Biopharma. MarketBeat recorded 8 mentions for Medicus Pharma and 4 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.37 beat Medicus Pharma's score of 0.30 indicating that Redhill Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Redhill Biopharma has a beta of 4.98, indicating that its share price is 398% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market.

Summary

Redhill Biopharma beats Medicus Pharma on 9 of the 14 factors compared between the two stocks.

Get Redhill Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDHL vs. The Competition

Export

Metric	Redhill Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.10M	$2.99B	$6.50B	$12.36B
Dividend Yield	N/A	1.76%	2.67%	5.67%
P/E Ratio	0.00	18.55	23.99	24.69
Price / Sales	14.14	464.28	538.03	166.93
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	0.95	4.02	10.47	6.82
Net Income	-$430K	$75.79M	$3.56B	$337.45M
7 Day Performance	-22.55%	2.31%	1.21%	2.49%
1 Month Performance	-23.30%	0.02%	2.14%	4.37%
1 Year Performance	-54.86%	24.02%	26.24%	32.80%

Redhill Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RDHL Redhill Biopharma	1.0174 of 5 stars	$0.79 -2.5%	N/A	-53.7%	$4.10M	$290K	0.00	210
ALVR AlloVir	N/A	$4.17 -6.1%	N/A	+64.0%	$21.03M	N/A	N/A	110	High Trading Volume
CLRB Cellectar Biosciences	4.4095 of 5 stars	$2.36 -6.0%	$11.00 +366.1%	-82.0%	$20.06M	N/A	N/A	10	Positive News Gap Up
MYNZ Mainz Biomed	N/A	$2.20 -5.6%	N/A	-5.5%	$19.93M	$659.94K	N/A	30	High Trading Volume
XCUR Exicure	0.9807 of 5 stars	$2.85 -4.7%	N/A	-68.3%	$19.06M	$500K	N/A	50	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RDHL) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Redhill Biopharma (RDHL) Competitors

RDHL vs. ALVR, CLRB, MYNZ, XCUR, and MDCX

How does Redhill Biopharma compare to AlloVir?

Summary

How does Redhill Biopharma compare to Cellectar Biosciences?

Summary

How does Redhill Biopharma compare to Mainz Biomed?

Summary

How does Redhill Biopharma compare to Exicure?

Summary

How does Redhill Biopharma compare to Medicus Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Redhill Biopharma (RDHL) Competitors

RDHL vs. ALVR, CLRB, MYNZ, XCUR, and MDCX

How does Redhill Biopharma compare to AlloVir?

Do analysts rate RDHL or ALVR?

Which has more volatility and risk, RDHL or ALVR?

Does the media prefer RDHL or ALVR?

Do insiders & institutionals believe in RDHL or ALVR?

Is RDHL or ALVR more profitable?

Which has higher valuation and earnings, RDHL or ALVR?

Summary

How does Redhill Biopharma compare to Cellectar Biosciences?

Do analysts prefer CLRB or RDHL?

Which has preferable earnings and valuation, CLRB or RDHL?

Is CLRB or RDHL more profitable?

Do insiders and institutionals have more ownership in CLRB or RDHL?

Does the media refer more to CLRB or RDHL?

Which has more risk and volatility, CLRB or RDHL?

Summary

How does Redhill Biopharma compare to Mainz Biomed?

Do insiders and institutionals believe in MYNZ or RDHL?

Is MYNZ or RDHL more profitable?

Do analysts prefer MYNZ or RDHL?

Which has more volatility & risk, MYNZ or RDHL?

Which has stronger valuation and earnings, MYNZ or RDHL?

Does the media favor MYNZ or RDHL?

Summary

How does Redhill Biopharma compare to Exicure?

Do analysts recommend XCUR or RDHL?

Which has more risk and volatility, XCUR or RDHL?

Is XCUR or RDHL more profitable?

Does the media favor XCUR or RDHL?

Do institutionals and insiders believe in XCUR or RDHL?

Which has better valuation and earnings, XCUR or RDHL?

Summary

How does Redhill Biopharma compare to Medicus Pharma?

Do analysts recommend RDHL or MDCX?

Do institutionals & insiders hold more shares of RDHL or MDCX?

Which has better valuation and earnings, RDHL or MDCX?

Is RDHL or MDCX more profitable?

Does the media prefer RDHL or MDCX?

Which has more volatility & risk, RDHL or MDCX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL vs. The Competition

Redhill Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools